Table 1. Characteristics of Patients Receiving HSCT.
| Characteristic | Total (N = 72) |
≥60% of Caloric Needs (n = 22) |
<60% of Caloric Needs (n = 50) |
P Value |
|---|---|---|---|---|
| Sex | .59 | |||
| Male | 46 (63.9) | 14 (63.6) | 32 (64.0) | |
| Female | 26 (36.1) | 8 (36.4) | 18 (36.0) | |
| Race | .44 | |||
| White | 47 (65.3) | 14 (63.6) | 33 (66.0) | |
| Black | 16 (22.2) | 4 (18.2) | 12 (24.0) | |
| Asian | 1 (1.4) | 1 (4.5) | 0 | |
| Hispanic | 8 (11.1) | 3 (13.6) | 5 (10.0) | |
| Age, mean ± SD, y | ||||
| Total | 54.9 ± 11.8 | 56.6 ± 8.7 | 54.1 ± 12.9 | .42 |
| Autologous | 55.7 ± 13.1 | 59.6 ± 10.4 | 54.6 ± 13.7 | .25 |
| Allogeneic | 51.9 ± 7.7 | 53.4 ± 4.5 | 50.0 ± 10.8 | .44 |
| MUDa | 54.7 ± 5.5 | 51.5 ± 2.1 | 56.3 ± 6.2 | .37 |
| BMI, median (IQR) | 28.0 (24.4–32.3) | 25.3 (23.5–31.5) | 28.4 (25.2–33.4) | .07 |
| BMI category | .19a | |||
| Underweight | 0 | 0 | 0 | |
| Normal | 20 (27.8) | 10 (45.5) | 10 (20.0) | |
| Overweight | 26 (36.1) | 5 (22.7) | 21 (42.0) | |
| Obesity grade I | 15 (20.8) | 5 (22.7) | 10 (20.0) | |
| Obesity grade II | 7 (9.7) | 1 (4.5) | 6 (12.0) | |
| Obesity grade III | 4 (5.6) | 1 (4.5) | 3 (6.0) | |
| Type of HSCT | .07 | |||
| Autologous | 52 (72.2) | 12 (54.5) | 40 (80.0) | |
| Allogeneic | 14 (19.4) | 8 (36.4) | 6 (12.0) | |
| MUD | 6 (8.3) | 2 (9.1) | 4 (8.0) | |
| Diagnosis | ||||
| Multiple myeloma | 30 (41.7) | 10 (45.5) | 20 (40.0) | .04b |
| Lymphoma | 26 (36.1) | 3 (13.6) | 23 (46.0) | |
| Acute leukemia | 13 (18.1) | 7 (31.8) | 6 (12.0) | |
| Myelofibrosis | 2 (2.8) | 1 (4.5) | 1 (2.0) | |
| CLL/SLL | 1 (1.4) | 1 (4.5) | 0 | |
| Conditioning regimen | .015c | |||
| Melphalan | 29 (40.3) | 10 (45.5) | 19 (38.0) | |
| BEAM | 17 (23.6) | 1 (4.5) | 16 (32.0) | |
| Fludarabine/melphalan | 13 (18.1) | 7 (31.8) | 6 (12.0) | |
| BendaEAM | 5 (6.9) | 1 (4.5) | 4 (8.0) | |
| Busulfan/fludarabine | 4 (5.6) | 3 (13.6) | 1 (2.0) | |
| Total-body irradiationd | 3 (4.2) | 0 | 3 (6.0) | |
| Ara-C | 1 (1.4) | 0 | 1 (2.0) |
Values are presented as number (%) unless otherwise indicated. BEAM, BCNU (carmustine), etoposide, Ara-C (cytarabine), and melphalan; BendaEAM, bendamustine, etoposide, cytarabine, and melphalan; BMI, body mass index; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; HSCT, hematopoietic stem cell transplant; IQR, interquartile range; MUD, matched unrelated donor.
a
χ2 Analysis between normal, overweight, and obese; P > .05.
b
χ2 Analysis between lymphoma, multiple myeloma, and acute leukemia; P < .05.
c
χ2 Analysis between melphalan, BEAM, and fludarabine/melphalan; P < .05.
d
Total-body irradiation plus additional chemotherapy agents, including fluarabine, cytoxan, and/or cyclophosphamide.